Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects

Minghao Dang, Hans C. Lee, Hima Bansal, Maria Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Rueda, David Berrios, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 767.

https://doi.org/10.1182/blood-2024-204313

Published: 2024

Journal Articles

Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma

Wei Tan, Minghao Dang, Upasana Ray, Luz Yurany Moreno Rueda, Maria Jose Acevedo-Calado, Hua Wang, Jun Wei, Li Qin, Isere Kuiatse, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 4640.

https://doi.org/10.1182/blood-2024-207917

Published: 2024

Journal Articles

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Minghao Dang, Hans C. Lee, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Rueda, David Berrios, Oren Pasvolsky, Mahmoud R. Gaballa, Melody R. Becnel, J Christine Ye, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2024-210080

Published: 2024

Journal Articles

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Minghao Dang, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Moreno Rueda, Mei Huang, David Berrios Nolasco, Hans C. Lee, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 89.

https://doi.org/10.1182/blood-2023-182902

Published: 2023

Journal Articles

Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit (CLPP) As a Novel Mediator of, and Target in High Risk Multiple Myeloma

Li Qin, Luz Yurany Moreno Rueda, Iqbal Mahmud, Isere Kuiatse, Wei Tan, Hans C. Lee, Krina K. Patel, David E. Symer, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2023-190766

Published: 2023

Journal Articles

Inhibition of Rho-Associated Coiled-Coil Containing Protein Kinases with Belumosudil Mesylate Shows Anti-Tumor and Immune Modulatory Properties in Models of Multiple Myeloma

Pankaj Kumar Singh, Frances N. Cervoni Curet, Cody T. Clayhold, Isere Kuiatse, Wei Tan, Marco Meloni, Monsif Bouaboula, Kamlesh Bisht, Helgi J. Van de Velde, Marielle Chiron, Angela Virone-Oddos, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 4689.

https://doi.org/10.1182/blood-2023-188317

Published: 2023

Journal Articles

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Minghao Dang, Li Qin, Wei Tan, Liping Dong, Hans C. Lee, Krina Patel, Luz Yurany Moreno Rueda, Pei Lin, Hima Bansal, David Berrios, Sheeba K Thomas, Donna M. Weber, David E. Symer, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 7122–7124.

https://doi.org/10.1182/blood-2022-165540

Published: 2022

Journal Articles

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Mark G. Faber, DO, Amanda Przespolewski, DO, Jeffrey Baron, PharmD, Tara Cronin, BA, Wei Tan, MS, James E. Thompson, MD, Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Swapna Thota, MD

Blood (2018) 132 (Supplement 1): 4366.

https://doi.org/10.1182/blood-2018-99-110846

Published: 2018

Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3975.

https://doi.org/10.1182/blood.V126.23.3975.3975

Published: 2015

Journal Articles

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Elizabeth A. Griffiths, MD, William Brady, Wei Tan, Carlos E Vigil, MD, James E. Thompson, MD, Laurie A Ford, BS, CCRC, Noelle M Dickey, BS, Jill Sperrazza, BS, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2014) 124 (21): 2318.

https://doi.org/10.1182/blood.V124.21.2318.2318

Published: 2014

Journal Articles

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Eunice S. Wang, MD, Gerald Fetterly, PhD, William Brady, Wei Tan, Jessica Greene, Allison Gaudy, Carlos E Vigil, MD, Jason H. Mendler, MD, PhD, Michael W. Becker, MD, Kristen O'Dwyer, MD, Jane L. Liesveld, MD, Meir Wetzler, MD

Blood (2013) 122 (21): 2701.

https://doi.org/10.1182/blood.V122.21.2701.2701

Published: 2013

Journal Articles

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Cecilia Y. Arana Yi, MD, Wei Tan, Ph.D., Gregory Wilding, Ph.D., Laurie Ann Ford, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, George Deeb, MD, Paul K. Wallace, MS, PhD, Petr Starostik, MD, James E. Thompson, MD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2009) 114 (22): 4129.

https://doi.org/10.1182/blood.V114.22.4129.4129

Published: 2009

Journal Articles

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.

Taimur Sher, MD, Kena C Miller, Sikander Ailawadhi, MD, Debbie Manfredi, Margaret Wood, Wei Tan, Ph.D., Gregory Wilding, Ph.D., Hong Liu, MD, Myron S Czuczman, MD, Francisco Hernandez, MD, Frederick Hong, MD, Raman Sood, MD, Saif Soniwalla, MD, William Lawrence, MD, Peter A. Kouides, MD, Kelvin P. Lee, MD, Asher Chanan-Khan, MD

Blood (2009) 114 (22): 618.

https://doi.org/10.1182/blood.V114.22.618.618

Published: 2009

Journal Articles

Myeloid Blastic Transformation of Myeloproliferative Neoplasms – A Review of 113 Cases.

Syed Noor, MD, Wei Tan, PhD, Gregory Wilding, PhD, Laurie Ann Ford, Maurice Barcos, MD, PhD, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, James E. Thompson, MD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2009) 114 (22): 3113.

https://doi.org/10.1182/blood.V114.22.3113.3113

Published: 2009

Journal Articles

Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction

Michael L. Chen, T. Daniel Logan, Maryann L. Hochberg, Suresh G. Shelat, Xiang Yu, Gregory E. Wilding, Wei Tan, Gregory C. Kujoth, Tomas A. Prolla, Mary A. Selak, Mondira Kundu, Martin Carroll, James E. Thompson

Blood (2009) 114 (19): 4045–4053.

https://doi.org/10.1182/blood-2008-08-169474

Published: 2009

Journal Articles

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

Mehul Patel, Taimur Sher, Sikander Ailawadhi, Terry Mashtare, Jr., Wei Tan, Pranay Soni, Gregory Wilding, Kena C Miller, Alice Mohr, Kelvin P. Lee, Asher Alban Chanan-Khan

Blood (2008) 112 (11): 2726.

https://doi.org/10.1182/blood.V112.11.2726.2726

Published: 2008

Journal Articles

High Body Surface Area (BSA) Is An Independent Risk Factor for Developing Bisphosphonate-Induced Osteonecrosis of the Jaw (ONJ)

Sikander Ailawadhi, Angie Elefante, Tracey L. O’Connor, Gregory E. Wilding, Wei Tan, Ellen Kossoff, Stephanie McCuthcheon, Kena C. Miller, Taimur Sher, Mehul Patel, Kelvin Lee, Asher A. Chanan-Khan

Blood (2008) 112 (11): 2786.

https://doi.org/10.1182/blood.V112.11.2786.2786

Published: 2008

Journal Articles

BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (≥60 years) Patients.

Shannon L Smiley, MD, Theresa Hahn, PhD, Wei Tan, MS, Gregory Wilding, PhD, Minoo Battiwalla, MD, Philip L. McCarthy, Jr., MD

Blood (2008) 112 (11): 2176.

https://doi.org/10.1182/blood.V112.11.2176.2176

Published: 2008

Journal Articles

Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).

Amer Zeidan, Wei Tan, Gregory Wilding, LaurieAnn Ford, Theresa Hahn, PhD, Shannon Smiley, MD, Minoo Battiwalla, MD, Philip L. McCarthy, MD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2008) 112 (11): 952.

https://doi.org/10.1182/blood.V112.11.952.952

Published: 2008

Journal Articles

Biologic Features and Treatment Outcome of Secondary Acute Lymphoblastic Leukemia - Review of 101 Cases.

Ranga Shivakumar, MD, Wei Tan, MS, Gregory Wilding, PhD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2007) 110 (11): 4345.

https://doi.org/10.1182/blood.V110.11.4345.4345

Published: 2007

NARROW

Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects

Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit (CLPP) As a Novel Mediator of, and Target in High Risk Multiple Myeloma

Inhibition of Rho-Associated Coiled-Coil Containing Protein Kinases with Belumosudil Mesylate Shows Anti-Tumor and Immune Modulatory Properties in Models of Multiple Myeloma

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.

Myeloid Blastic Transformation of Myeloproliferative Neoplasms – A Review of 113 Cases.

Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

High Body Surface Area (BSA) Is An Independent Risk Factor for Developing Bisphosphonate-Induced Osteonecrosis of the Jaw (ONJ)

BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (≥60 years) Patients.

Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).

Biologic Features and Treatment Outcome of Secondary Acute Lymphoblastic Leukemia - Review of 101 Cases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only